{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "San Diego",
      "state": "CA",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "64198",
      "recalling_firm": "Pacira Pharmaceuticals, Inc.",
      "address_1": "10450 Science Center Dr",
      "address_2": "N/A",
      "postal_code": "92121-1119",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",
      "distribution_pattern": "Nationwide distribution: AZ, DC, FL, GA, MA, NJ, NY, OH, and TX.",
      "recall_number": "D-168-2013",
      "product_description": "EXPAREL (bupivacaine liposome injectable suspension),  1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA",
      "product_quantity": "324 vials",
      "reason_for_recall": "Subpotent; bupivacaine",
      "recall_initiation_date": "20121217",
      "center_classification_date": "20130225",
      "termination_date": "20130503",
      "report_date": "20130306",
      "code_info": "Lot #11-2005  Control #23542  Manufacture Date: 05Dec11  2011-L-009"
    }
  ]
}